Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

3.8K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.8K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

1.8K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

620
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
620
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

890
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
890
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

444
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influenza and the work of the World Health Organization.

Vaccine·2002
Same author

Estimate of the global market for rifampicin-containing fixed-dose combination tablets.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·1999
Same author

Availability of quality fixed-dose combinations for the treatment of tuberculosis: what can we learn from studying the World Health Organization's vaccine model?

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·1999
Same author

The changing face of hypertension and antihypertensive agents.

Drugs & aging·1996
Same author

Clinical trials and transethnic pharmacology.

Drug safety·1994
Same author

Elderly hypertensives and quality of life: some methodological considerations.

European heart journal·1993
Same journal

Disrupted erythrocyte S1P-eNOS axis promotes hypoxia, hypertension and fibrosis in obstructive sleep apnoea-hypopnoea syndrome.

European heart journal·2026
Same journal

Stroke and systemic embolism following AF ablation: importance of global registries.

European heart journal·2026
Same journal

Update on lipoprotein(a): the rising star in residual lipid risk.

European heart journal·2026
Same journal

Great debate: medical treatment of heart failure with reduced ejection fraction will rely on four foundational drugs.

European heart journal·2026
Same journal

The surgical collateralization theory: has the beautiful hypothesis been killed by the ugly facts?

European heart journal·2026
Same journal

Beyond single measurement: additional considerations for high-sensitivity C-reactive protein in cardiovascular risk prediction.

European heart journal·2026
See all related articles

Related Experiment Video

Updated: May 2, 2026

Sex Stratified Neuronal Cultures to Study Ischemic Cell Death Pathways
10:44

Sex Stratified Neuronal Cultures to Study Ischemic Cell Death Pathways

Published on: December 10, 2013

11.9K

Coronary disease: are there gender differences?

M E Kitler1

  • 1Associates for Business Research (ABR), Maison des Truites, Gilly, Switzerland.

European Heart Journal
|March 1, 1994
PubMed
Summary
This summary is machine-generated.

Women experience higher rates of hypertensive heart disease and increased mortality after acute myocardial infarction (MI). Clinical trials often exclude women, leading to under-treatment and ineffective interventions for coronary heart disease (CHD).

More Related Videos

Ultrasound Based Assessment of Coronary Artery Flow and Coronary Flow Reserve Using the Pressure Overload Model in Mice
06:39

Ultrasound Based Assessment of Coronary Artery Flow and Coronary Flow Reserve Using the Pressure Overload Model in Mice

Published on: April 13, 2015

14.8K
Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

3.6K

Related Experiment Videos

Last Updated: May 2, 2026

Sex Stratified Neuronal Cultures to Study Ischemic Cell Death Pathways
10:44

Sex Stratified Neuronal Cultures to Study Ischemic Cell Death Pathways

Published on: December 10, 2013

11.9K
Ultrasound Based Assessment of Coronary Artery Flow and Coronary Flow Reserve Using the Pressure Overload Model in Mice
06:39

Ultrasound Based Assessment of Coronary Artery Flow and Coronary Flow Reserve Using the Pressure Overload Model in Mice

Published on: April 13, 2015

14.8K
Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

3.6K

Area of Science:

  • Cardiovascular Medicine
  • Clinical Trials
  • Gender-Based Health Disparities

Background:

  • Hypertensive heart disease prevalence is higher in women, while coronary heart disease (CHD) is more prevalent in men.
  • Female gender is linked to increased mortality following acute myocardial infarction (MI).
  • Observed differences in treatment response between sexes necessitate further investigation.

Purpose of the Study:

  • To highlight the disparities in cardiovascular disease prevalence and outcomes between men and women.
  • To address the underrepresentation of females in clinical trials for CHD.
  • To emphasize the need for sex-specific research in cardiovascular disease prevention and treatment.

Main Methods:

  • Review of existing epidemiological data on cardiovascular disease prevalence by gender.
  • Analysis of clinical trial methodologies concerning female participant inclusion.
  • Examination of treatment efficacy data stratified by gender.

Main Results:

  • Women exhibit higher rates of hypertensive heart disease, whereas men show higher rates of coronary heart disease.
  • Surgical and pharmacological interventions for CHD appear less effective in females compared to males.
  • Inadequate female representation in clinical trials hinders the development of effective, sex-specific treatment strategies.

Conclusions:

  • Extrapolating findings from male-dominated studies to female populations is scientifically unsound.
  • Further research is crucial to establish optimal intervention strategies for primary prevention and treatment of coronary disease in women and the elderly.
  • Addressing gender-based differences in cardiovascular disease is essential for improving patient outcomes.